A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in Patients with Previously Untre...

Title A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in Patients with Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer

Contact EF

Principal Investigator Grace Dy, MD

Study Number 208911

Phase2

Summary

The purpose of this study is to find out the effects, good and/or bad, of GDC-0941 NSCLC when GDC-0941 is cobmined with other drugs intended for treatment, compared to these other drugs alone. In this study, patients receive carboplatin and paclitaxel as chemotherapy. If the NSCLC is of the non-squamous type, patients will also receive bevacizumab. Patients will either receive GDC-0941 or a placebo (a tablet that looks like GDC-0941 but that has no active ingredient). GDC-0941 is a drug that blocks a protein called P13-kinase that may be involved in the growth and spread of some cancers. In animal studies and laboratory experiments, GDC-0941 has been shown to prevent or slow the growth of many different types of human cancer cells. GDC-0941 is currently being tested in clinical studies in people with advanced cancer.

Eligibility SEE CLINICALTRIALS.GOV LISTING

For more information about the clinical study go to Clinicaltrial.Gov